AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10828725 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein kinase C activation with 4beta‐12‐tetradecanoylphorbol 13‐acetate (beta‐TPA)
Number of subjects: 15
Study 10828725 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 15
Study 9603637 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin 800 mg once-daily (Group A)
Number of subjects: 86
Study 9603637 — intervention group
Group type: COMPARATOR
Intervention: Norfloxacin 400 mg twice-daily (Group B)
Number of subjects: 86
Study 7930762 — intervention group
Group type: EXPERIMENTAL
Intervention: High HAMA levels in serum
Number of subjects: 0
Study 7930762 — intervention group
Group type: COMPARATOR
Intervention: Low HAMA levels in serum
Number of subjects: 0
Study 3350994 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (PN) 10-mg oral tablet
Number of subjects: 8
Study 3350994 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (PL) 10-mg oral tablet
Number of subjects: 8
Study 3350994 — intervention group
Group type: COMPARATOR
Intervention: Intravenous Prednisone (IV PN) 10-mg
Number of subjects: 8
Study 3350994 — intervention group
Group type: COMPARATOR
Intervention: Intravenous Prednisolone (IV PL) 10-mg
Number of subjects: 8
Study 28548898 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid albuterol pathway with a breath-enhanced nebulizer (up to 4 treatments)
Number of subjects: 50
Study 28548898 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment arm (up to 2 continuous albuterol nebulizations)
Number of subjects: 50
Study 26059708 — intervention group
Group type: EXPERIMENTAL
Intervention: RC Fill (zinc oxide‐eugenol with iodoform)
Number of subjects: 129
Study 26059708 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitapex (calcium hydroxide with iodoform)
Number of subjects: 129
Study 26059708 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulpdent root canal sealer (ZOE)
Number of subjects: 129
Study 25211372 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga intervention (12 sessions)
Number of subjects: 0
Study 25211372 — intervention group
Group type: COMPARATOR
Intervention: Assessment control
Number of subjects: 0
Study 25211372 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga intervention
Number of subjects: 0
Study 22945731 — intervention group
Group type: EXPERIMENTAL
Intervention: Irrigation with a hydroalcoholic solution of propolis extract twice a week for 2 weeks (group A)
Number of subjects: 20
Study 22945731 — intervention group
Group type: COMPARATOR
Intervention: Irrigation with a placebo twice a week for 2 weeks (group B)
Number of subjects: 20
Study 22945731 — intervention group
Group type: COMPARATOR
Intervention: No additional treatment (group C)
Number of subjects: 20
Study 20490472 — intervention group
Group type: EXPERIMENTAL
Intervention: Blonanserin 2 mg oral dose, administered under different conditions: fasting, 30 min before meal, 30 min after meal, 2 h after meal, 4 h after meal.
Number of subjects: 0
Study 18323713 — intervention group
Group type: EXPERIMENTAL
Intervention: Sun-style 24 forms of Tai Chi exercise for 60 min, 2 times per week for 12 weeks
Number of subjects: 46
Study 18323713 — intervention group
Group type: EXPERIMENTAL
Intervention: Sun-style 24 forms of Tai Chi exercise
Number of subjects: 46
Study 18323713 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 46
Study 15785958 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol 200 mug
Number of subjects: 20
Study 15785958 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 15785958 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric exercise
Number of subjects: 20
Study 12131653 — intervention group
Group type: EXPERIMENTAL
Intervention: Study group (direct contact)
Number of subjects: 2025
Study 12131653 — intervention group
Group type: COMPARATOR
Intervention: Standard group (invitation letter)
Number of subjects: 2025
Study 7559202 — intervention group
Group type: EXPERIMENTAL
Intervention: Rufloxacin 400 mg
Number of subjects: 0
Study 7559202 — intervention group
Group type: COMPARATOR
Intervention: Norfloxacin 400 mg
Number of subjects: 0
Study 2783493 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture-like transcutaneous electrical nerve stimulation (TENS) for 30 minutes
Number of subjects: 21
Study 2783493 — intervention group
Group type: COMPARATOR
Intervention: Placebo pill
Number of subjects: 21
Study 1092151 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional acupuncture (Ho‐Ku, LI4; Nei‐Kuan, EH‐6)
Number of subjects: 12
Study 1092151 — intervention group
Group type: COMPARATOR
Intervention: Needling of arbitrarily chosen points
Number of subjects: 12
Study 31373374 — intervention group
Group type: EXPERIMENTAL
Intervention: FFR + CSB
Number of subjects: 3535
Study 31373374 — intervention group
Group type: EXPERIMENTAL
Intervention: RFR + CSB
Number of subjects: 3535
Study 31373374 — intervention group
Group type: EXPERIMENTAL
Intervention: NFR + CSB
Number of subjects: 3535
Study 31373374 — intervention group
Group type: EXPERIMENTAL
Intervention: FFR + LNS
Number of subjects: 3535
Study 31373374 — intervention group
Group type: EXPERIMENTAL
Intervention: FFR + MNP
Number of subjects: 3535
Study 31373374 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 3535
Study 28967627 — intervention group
Group type: EXPERIMENTAL
Intervention: Agar‐35 tea (n=6)
Number of subjects: 14
Study 28967627 — intervention group
Group type: COMPARATOR
Intervention: Placebo tea (n=8)
Number of subjects: 14
Study 26334929 — intervention group
Group type: EXPERIMENTAL
Intervention: STRIDE lifestyle intervention (weekly group meetings for 6 months, then monthly for 6 months)
Number of subjects: 0
Study 26334929 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 26334929 — intervention group
Group type: EXPERIMENTAL
Intervention: STRIDE lifestyle intervention
Number of subjects: 0
Study 23492960 — intervention group
Group type: EXPERIMENTAL
Intervention: Prebifurcation (PB) technique
Number of subjects: 68
Study 23492960 — intervention group
Group type: COMPARATOR
Intervention: Bifurcation (B) technique
Number of subjects: 68
Study 21198745 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (patients on dopamine agonist therapy)
Number of subjects: 40
Study 21198745 — intervention group
Group type: COMPARATOR
Intervention: Group A (control subjects)
Number of subjects: 40
Study 19101780 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan (RAS inhibitor)
Number of subjects: 462
Study 19101780 — intervention group
Group type: COMPARATOR
Intervention: Antihypertensive drugs without RAS inhibitors
Number of subjects: 462
Study 17876013 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab, bevacizumab, and irinotecan (CBI)
Number of subjects: 83
Study 17876013 — intervention group
Group type: COMPARATOR
Intervention: Cetuximab and bevacizumab alone (CB)
Number of subjects: 83
Study 15237752 — intervention group
Group type: EXPERIMENTAL
Intervention: Perturbed treadmill training
Number of subjects: 29
Study 15237752 — intervention group
Group type: COMPARATOR
Intervention: Ordinary treadmill training
Number of subjects: 29
Study 11237807 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 147
Study 11237807 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study 9934233 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol and complementary antimicrobial therapeutics
Number of subjects: 20
Study 7823116 — intervention group
Group type: EXPERIMENTAL
Intervention: Pointing task (reproduction by pointing)
Number of subjects: 0
Study 7823116 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual reproduction (using two visual stimuli)
Number of subjects: 0
Study 7823116 — intervention group
Group type: COMPARATOR
Intervention: Both conditions (pointing and visual reproduction)
Number of subjects: 0
Study 3370020 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-week program of submaximal aerobic exercise three times weekly
Number of subjects: 55
Study 3370020 — intervention group
Group type: COMPARATOR
Intervention: Nonexercising control group
Number of subjects: 55
Study 331853 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine
Number of subjects: 25
Study 331853 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 31366395 — intervention group
Group type: EXPERIMENTAL
Intervention: Online home-based cognitive training (13 games focusing on executive functions, attention, and processing speed)
Number of subjects: 140
Study 31366395 — intervention group
Group type: COMPARATOR
Intervention: Active control (3 games to keep participants cognitively engaged without training)
Number of subjects: 140
Study 31366395 — intervention group
Group type: EXPERIMENTAL
Intervention: Online home-based cognitive training
Number of subjects: 140
Study 31366395 — intervention group
Group type: COMPARATOR
Intervention: Active control
Number of subjects: 140
Study 25084971 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic group (first-line antibiotics for 3 days)
Number of subjects: 250
Study 25084971 — intervention group
Group type: COMPARATOR
Intervention: No Antibiotic group
Number of subjects: 250
Study 25084971 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 250
Study 22345687 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin (2 mg initially, increasing to 4 mg after 8 weeks if necessary)
Number of subjects: 545
Study 22345687 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin (2 and 4 mg)
Number of subjects: 545
Study 22157744 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided interfascial injection of 5 mL of lidocaine 2%
Number of subjects: 50
Study 22157744 — intervention group
Group type: COMPARATOR
Intervention: Nerve stimulation-assisted technique with 5 mL of lidocaine 2%
Number of subjects: 50
Study 20501476 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycoprotein IIb/IIIa inhibitors (abciximab, eptifibatide, tirofiban) administered pre-sheath (before catheterization laboratory arrival)
Number of subjects: 5707
Study 20501476 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycoprotein IIb/IIIa inhibitors (abciximab, eptifibatide, tirofiban) administered in-lab (after catheterization laboratory arrival)
Number of subjects: 5707
Study 17711924 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral estrogen (17beta-estradiol) at doses of 0.5, 1, and 2 mg for 2 weeks each
Number of subjects: 11
Study 17711924 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estrogen (TD) at doses of 0.025, 0.0375, and 0.05 mg for 2 weeks each
Number of subjects: 11
Study 16334438 — intervention group
Group type: EXPERIMENTAL
Intervention: L-NMMA (4 mg kg-1 h-1)
Number of subjects: 7
Study 16334438 — intervention group
Group type: COMPARATOR
Intervention: Saline (0.9%)
Number of subjects: 7
Study 11728834 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproheptadine
Number of subjects: 18
Study 11728834 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 18
Study 9620107 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy
Number of subjects: 0
Study 8131535 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing and coughing exercises with physiotherapist supervision (Group 2)
Number of subjects: 120
Study 8131535 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing and coughing exercises with more frequent physiotherapist supervision (Group 3)
Number of subjects: 120
Study 8131535 — intervention group
Group type: COMPARATOR
Intervention: No preoperative or postoperative chest physiotherapy (Group 1)
Number of subjects: 120
Study 2478015 — intervention group
Group type: EXPERIMENTAL
Intervention: ATIII/heparin regimen (1,500 units preoperatively and 1,000 units daily for five days)
Number of subjects: 31
Study 2478015 — intervention group
Group type: EXPERIMENTAL
Intervention: ATIII (same dose as hip replacement)
Number of subjects: 31
Study 2478015 — intervention group
Group type: EXPERIMENTAL
Intervention: ATIII (twice the dose used for hip replacement)
Number of subjects: 31
Study 2478015 — intervention group
Group type: COMPARATOR
Intervention: ATIII/heparin, warfarin, or dextran
Number of subjects: 31
Study 1266558 — intervention group
Group type: EXPERIMENTAL
Intervention: DHB 0.2 mg/kg
Number of subjects: 84
Study 1266558 — intervention group
Group type: COMPARATOR
Intervention: Pentobarbital 2 mg/kg
Number of subjects: 84
Study 1266558 — intervention group
Group type: COMPARATOR
Intervention: Halothane with pentobarbital 2 mg/kg
Number of subjects: 84
Study 31035902 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 10 mg/day
Number of subjects: 793
Study 31035902 — intervention group
Group type: COMPARATOR
Intervention: Control (nonstatin treatment)
Number of subjects: 793
Study 26711466 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthwash and a moisturizing gel (M + m)
Number of subjects: 60
Study 26711466 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthwash (M)
Number of subjects: 60
Study 26711466 — intervention group
Group type: EXPERIMENTAL
Intervention: Water and a moisturizing gel (W + m)
Number of subjects: 60
Study 26711466 — intervention group
Group type: COMPARATOR
Intervention: Water (W)
Number of subjects: 60
Study 27099884 — intervention group
Group type: EXPERIMENTAL
Intervention: Ongoing GDMT plus carotid baroreflex activation therapy (BAT) for 6 months
Number of subjects: 146
Study 27099884 — intervention group
Group type: COMPARATOR
Intervention: Ongoing GDMT alone for 6 months
Number of subjects: 146
Study 23484763 — intervention group
Group type: EXPERIMENTAL
Intervention: Bepotastine besilate ophthalmic solution (BBOS) 1.5%
Number of subjects: 0
Study 23484763 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22379790 — intervention group
Group type: EXPERIMENTAL
Intervention: Plum-blossom needle tapping plus cupping
Number of subjects: 60
Study 22379790 — intervention group
Group type: COMPARATOR
Intervention: He-Ne laser irradiation
Number of subjects: 60
Study 19663092 — intervention group
Group type: EXPERIMENTAL
Intervention: Suspended moxibustion at Baihui (GV 20)
Number of subjects: 75
Study 19663092 — intervention group
Group type: COMPARATOR
Intervention: Estazolam (oral administration)
Number of subjects: 75
Study 16988594 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg Delta‐9‐THC
Number of subjects: 6
Study 16988594 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg CBD
Number of subjects: 6
Study 16988594 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg CBD
Number of subjects: 6
Study 16988594 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 12949690 — intervention group
Group type: EXPERIMENTAL
Intervention: Proproten-100
Number of subjects: 0
Study 11035338 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard corticosteroid dosage regimen for promotion of fetal lung maturation
Number of subjects: 37
Study 11035338 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose corticosteroid regimen of >24 mg/d (10 mg dexamethasone IV every 6 hours for 2 doses followed by 6 mg IV every 6 hours for 2 to 4 doses)
Number of subjects: 37
Study 11035338 — intervention group
Group type: COMPARATOR
Intervention: No corticosteroids
Number of subjects: 37
Study 9447770 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate 0-6 gel (400 ppm F)
Number of subjects: 53
Study 9447770 — intervention group
Group type: COMPARATOR
Intervention: Colgate Great Regular Flavour (GRF) (1450 ppm F)
Number of subjects: 53
Study 9447770 — intervention group
Group type: EXPERIMENTAL
Intervention: Smear instruction
Number of subjects: 53
Study 9447770 — intervention group
Group type: COMPARATOR
Intervention: Pea-sized instruction
Number of subjects: 53
Study 8417421 — intervention group
Group type: EXPERIMENTAL
Intervention: Sultamicillin
Number of subjects: 144
Study 8417421 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin-clavulanate
Number of subjects: 144
Study 3087861 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone 500 mg
Number of subjects: 172
Study 3087861 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone 250 mg
Number of subjects: 172
Study 3087861 — intervention group
Group type: COMPARATOR
Intervention: Bicillin (procaine penicillin)
Number of subjects: 172
Study 29146890 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea ointment 3%
Number of subjects: 372
Study 29146890 — intervention group
Group type: COMPARATOR
Intervention: Placebo ointment
Number of subjects: 372
Study 27107670 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged-release melatonin
Number of subjects: 78
Study 27107670 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 27107670 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzodiazepine dosage reduction
Number of subjects: 78
Study 26862634 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral glutamine supplementation
Number of subjects: 60
Study 26862634 — intervention group
Group type: COMPARATOR
Intervention: Isonitrogenous arm (control)
Number of subjects: 60
Study 22908105 — intervention group
Group type: EXPERIMENTAL
Intervention: Moving to Opportunity (MTO) treatment (voucher for lower-poverty neighborhoods)
Number of subjects: 2829
Study 22908105 — intervention group
Group type: COMPARATOR
Intervention: Control group (no voucher)
Number of subjects: 2829
Study 20100810 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight management intervention with smoking cessation
Number of subjects: 284
Study 20100810 — intervention group
Group type: COMPARATOR
Intervention: Tests that do not require the MCAR assumption
Number of subjects: 284
Study 17882375 — intervention group
Group type: EXPERIMENTAL
Intervention: Stentless mitral valve (SMV)
Number of subjects: 155
Study 17882375 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitral valve repair (MV-rep)
Number of subjects: 155
Study 17882375 — intervention group
Group type: COMPARATOR
Intervention: Conventional mitral valve replacement (MVR)
Number of subjects: 155
Study 16293412 — intervention group
Group type: EXPERIMENTAL
Intervention: Dydrogesterone 40 mg stat dose followed by 10 mg twice a day for one week
Number of subjects: 154
Study 16293412 — intervention group
Group type: COMPARATOR
Intervention: Conservative therapy
Number of subjects: 154
Study 12199727 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-echo-time proton magnetic resonance spectroscopy imaging (MRSI)
Number of subjects: 30
Study 12199727 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 30
Study 10403975 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based nursing practices
Number of subjects: 0
Study 10403975 — intervention group
Group type: COMPARATOR
Intervention: Randomized controlled trials
Number of subjects: 0
Study 7502999 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma selenium levels in cases with MI (mean 114.4 ± 15.1 ng/g)
Number of subjects: 502
Study 7502999 — intervention group
Group type: COMPARATOR
Intervention: Plasma selenium levels in controls (mean 113.2 ± 15.7 ng/g)
Number of subjects: 502
Study 2102136 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin 20 mg b.i.d.
Number of subjects: 12
Study 2102136 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin 40 mg b.i.d.
Number of subjects: 12
Study 2102136 — intervention group
Group type: COMPARATOR
Intervention: Ketanserin 20 mg b.i.d. and 40 mg b.i.d.
Number of subjects: 12
Study 86158 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 10% adenine arabinoside 5'-monophosphate
Number of subjects: 233
Study 30668853 — intervention group
Group type: COMPARATOR
Intervention: 6L:18D
Number of subjects: 480
Study 30668853 — intervention group
Group type: EXPERIMENTAL
Intervention: 8L:16D
Number of subjects: 480
Study 30668853 — intervention group
Group type: EXPERIMENTAL
Intervention: 10L:14D
Number of subjects: 480
Study 30668853 — intervention group
Group type: EXPERIMENTAL
Intervention: ≥10 h photoperiods
Number of subjects: 480
Study 30668853 — intervention group
Group type: EXPERIMENTAL
Intervention: ≥8‐h photoperiods
Number of subjects: 480
Study 30668853 — intervention group
Group type: EXPERIMENTAL
Intervention: ≥12 h
Number of subjects: 480
Study 27582421 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Number of subjects: 219
Study 27582421 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 219
Study 26153671 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant-daily nevirapine
Number of subjects: 2369
Study 26153671 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal antiretroviral (zidovudine, lamivudine and either nevirapine, nelfinavir or lopinavir-ritonavir)
Number of subjects: 2369
Study 26153671 — intervention group
Group type: COMPARATOR
Intervention: No further antiretroviral prophylaxis (control arm)
Number of subjects: 2369
Study 23838656 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentric dilated LVH
Number of subjects: 939
Study 23838656 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric dilated LVH
Number of subjects: 939
Study 23838656 — intervention group
Group type: COMPARATOR
Intervention: Eccentric nondilated LVH
Number of subjects: 939
Study 21249332 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (ZOL) 5 mg
Number of subjects: 2127
Study 21249332 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2127
Study 21249332 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (ZOL)
Number of subjects: 2127
Study 19695526 — intervention group
Group type: EXPERIMENTAL
Intervention: Microcurrent therapy (30 minutes) followed by stretching exercises (2 minutes); 3 treatments per week for 2 weeks.
Number of subjects: 15
Study 19695526 — intervention group
Group type: COMPARATOR
Intervention: Stretching exercises after ultrasound therapy (30 minutes); 3 treatments per week for 2 weeks.
Number of subjects: 15
Study 15650862 — intervention group
Group type: EXPERIMENTAL
Intervention: aepEX
Number of subjects: 40
Study 15650862 — intervention group
Group type: EXPERIMENTAL
Intervention: bispectral index
Number of subjects: 40
Study 15650862 — intervention group
Group type: EXPERIMENTAL
Intervention: SEF95%
Number of subjects: 40
Study 15650862 — intervention group
Group type: EXPERIMENTAL
Intervention: aepEX, bispectral index, SEF95%
Number of subjects: 40
Study 12764910 — intervention group
Group type: EXPERIMENTAL
Intervention: Shengmai Injection (SMI) plus conventional treatment of western medicine
Number of subjects: 60
Study 12764910 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment alone
Number of subjects: 60
Study 10496553 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-positive patients
Number of subjects: 48